<DOC>
	<DOC>NCT00682305</DOC>
	<brief_summary>The present study is a multicenter, prospective phase II-study investigating the combination of treosulfan, etoposide, and cyclophosphamide as conditioning regimen for patients with acute lymphoblastic leukemia who are not eligible for a TBI-containing regimen.</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplantation (SCT) With Treosulfan, VP-16 and Cyclophosphamid for Patients With Acute Lymphoblastic Leukemia (ALL)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<criteria>Acute lymphoblastic leukemia in first or subsequent complete remission Indication for allogeneic stem cell transplantation according to the actual protocol of the German Acute Lymphoblastic Leukemia Study Group Patient's age: 1865 years HLAidentical or compatible related or unrelated donor (HLAA, HLAB, HLAC, HLADRB1 and HLADQB1) (one antigenmismatch allowed) Not eligible for totalbody irradiation due to one of the following reasons: prior radiation of the spine &gt; 30 Gy prior radiation of the mediastinum &gt; 30 Gy severe pulmonary infection during induction chemotherapy DLCO &gt; 50% Patient's wishing to avoid totalbody irradiation as conditioning regimen Patient's written informed consent Women and men capable of reproduction must agree to use highly effective methods of contraception until six months after treatment termination. For men: vasectomy, sexual abstinence, or partner is using hormonal IUD, implants, injectables, oral hormonal contraceptives or is surgically sterilized. For women: hormonal IUD, implants, injectables, sexual abstinence, surgical sterilization, vasectomised partner No complete remission at time of registration Severe irreversible renal, hepatic, pulmonary or cardiac disease, such as total bilirubin, SGPT or SGOT &gt; 3 times upper the normal level Left ventricular ejection fraction &lt; 30% Creatinine clearance &lt; 30 ml/min DLCO &lt; 35% and/ or receiving supplementary continuous oxygen Positive serology HIV Pregnant or lactating women Severe florid infection Experienced hypersensitivity against cyclophosphamid, etoposide, or treosulfan Cystitis Obstructive renal function Participation in any other clinical drug trial Serious psychiatric or psychological disorders Progressive invasive fungal infection at time of registration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Hematopoeitic Stem Cell Transplantation</keyword>
</DOC>